{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:54:49Z","timestamp":1790801689597,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.euf.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T02:10:46Z","timestamp":1555553446000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Gu\u00e9rin Connaught Strain for Bladder Cancer Patients"],"prefix":"10.1016","volume":"7","author":[{"given":"Said","family":"Ourfali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-7683","authenticated-orcid":false,"given":"Robin","family":"Ohannessian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Fassi-Fehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfreda","family":"Pages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Badet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0152-8021","authenticated-orcid":false,"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2019.04.002_bib0005","first-page":"7","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2019.04.002_bib0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0015","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0020","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0025","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0030","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.urology.2006.10.017","article-title":"Intravesical instillation of bacille Calmette-Gu\u00e9rin for superficial bladder cancer: cost-effectiveness analysis","volume":"69","author":"Uchida","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.euf.2019.04.002_bib0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/UA.UA_115_17","article-title":"Prognostic impact of bacillus Calmette-Gu\u00e9rin interruption at the time of induction and consolidation","volume":"9","author":"Alhogbani","year":"2017","journal-title":"Urol Ann"},{"key":"10.1016\/j.euf.2019.04.002_bib0055","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.urology.2008.12.039","article-title":"Discontinuance of bacille Calmette-Gu\u00e9rin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence","volume":"73","author":"Takeda","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.euf.2019.04.002_bib0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ypmed.2013.04.019","article-title":"BCG shortage in Europe","volume":"57","author":"Dal Moro","year":"2013","journal-title":"Prev Med"},{"key":"10.1016\/j.euf.2019.04.002_bib0065","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.euf.2019.04.002_bib0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euf.2019.04.002_bib0075","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/cncr.31246","article-title":"Cancer drug shortages: awareness and perspectives from a representative sample of the US population","volume":"124","author":"Frosch","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2019.04.002_bib0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.euf.2018.06.018","article-title":"Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Gu\u00e9rin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2019.04.002_bib0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bju.14065","article-title":"The impact of the global bacille Calmette-Gu\u00e9rin shortage on treatment patterns: population-based data","volume":"121","author":"Perera","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2019.04.002_bib0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2019.04.002_bib0100","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2019.04.002_bib0105","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0110","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2019.04.002_bib0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/BLC-180187","article-title":"Intravesical radiofrequency-induced chemohyperthermia for carcinoma in situ of the urinary bladder: a retrospective multicentre study","volume":"4","author":"van Valenberg","year":"2018","journal-title":"Bladder Cancer Amst Neth"},{"key":"10.1016\/j.euf.2019.04.002_bib0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0125","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0130","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.juro.2017.10.041","article-title":"Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma","volume":"199","author":"Siefker-Radtke","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2019.04.002_bib0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.euf.2018.07.005","article-title":"Combination intravesical chemotherapy for non-muscle-invasive bladder cancer","volume":"4","author":"Steinberg","year":"2018","journal-title":"Eur Urol Focus"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919301099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456919301099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:50:12Z","timestamp":1762498212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456919301099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2405456919301099"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2019.04.002","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Gu\u00e9rin Connaught Strain for Bladder Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}